BET inhibitors: a novel epigenetic approach (Q38609772)

4 September 2017

BET inhibitors: a novel epigenetic approach (English)

1 reference

4 September 2017

D B Doroshow

1

1 reference

4 September 2017

J P Eder

series ordinal

2

1 reference

4 September 2017

P M LoRusso

series ordinal

3

1 reference

4 September 2017

1 August 2017

1 reference

4 September 2017

1 reference

4 September 2017

28

1 reference

4 September 2017

1776-1787

1 reference

4 September 2017

8

1 reference

Perceptions of epigenetics

4 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

An operational definition of epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

The history of cancer epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Epigenetic changes in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Cancer epigenomics: DNA methylomes and histone-modification maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Epigenetics: A primer for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Chromatin modifications and their function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Targeting the histone orthography of cancer: drugs for writers, erasers and readers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Histone deacetylase inhibitors in hematological malignancies and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Two faces of brd4: mitotic bookmark and transcriptional lynchpin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Regulation of aurora B expression by the bromodomain protein Brd4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

BET domain co-regulators in obesity, inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Targeting bromodomains: epigenetic readers of lysine acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

The mechanisms behind the therapeutic activity of BET bromodomain inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Clinical progress and pharmacology of small molecule bromodomain inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Suppression of inflammation by a synthetic histone mimic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Selective inhibition of BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Master transcription factors and mediator establish super-enhancers at key cell identity genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Selective inhibition of tumor oncogenes by disruption of super-enhancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

The Myc oncoprotein as a therapeutic target for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Reflecting on 25 years with MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Targeting MYC dependence in cancer by inhibiting BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Targeting MYCN in neuroblastoma by BET bromodomain inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Concomitant BET and MAPK blockade for effective treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Overcoming Resistance to Targeted Therapies in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Mechanisms of tumor cell resistance to the current targeted-therapy agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX157

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDX157

1 reference

release_4cqzq5lpa5bbjcncdhfaiqkahi

4 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4cqzq5lpa5bbjcncdhfaiqkahi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference